News | September 09, 2025
Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The program will offer a structured and immersive learning experience for over 20,000 healthcare professionals across more than 10 cities
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Express Scripts to add Zepbound to National Preferred Formulary
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Subscribe To Our Newsletter & Stay Updated
